Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.

ABSTRACT: Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has undergone remarkable changes over the past 25 years. Small molecules (molecular weight of less than one kDa), together with newer immunotherapies that include monoclonal antibodies, antibody-drug conjugates, and most recently, chimeric antigen receptor (CAR) T-cells, have combined to double the disease's five-year survival rate to over 50% during the past few decades. Despite these advances, the disease is still considered incurable, and its treatment continues to pose substantial challenges, since therapeutic refractoriness and patient relapse are exceedingly common. This review focuses on the current pipeline, along with the contemporary roles and future prospects for small molecules in MM therapy. While small

SUBMITTER: Abramson HN 

PROVIDER: S-EPMC9917049 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature